Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$39.55M+2.21%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aaron D. Berg
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 80
- Beta
- 0.79
- Country
- IE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -2.06
Financials
Revenue
$39.55M+2.2%Net Income
$245.0KEBITDA
$954.0KFree Cash Flow
$9.22MEPS (diluted)
$0.23Shares Outstanding (diluted)
1.04M+54.7%Operating Expenses
$18.54MCash & Debt
$323.38MReturn of Capital
$0.00Revenue by Segment (annual)
$213.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $213.65M | $-38.80M | $-36.00 |
| 2024 | $228.61M | $-82.18M | $-80.00 |
| 2023 | $306.91M | $-59.11M | $-60.00 |
| 2022 | $369.19M | $-105.80M | $-104.00 |
| 2021 | $583.19M | $7.73M | $7.80 |
| 2020 | $614.06M | $-18.00M | $-18.88 |
| 2019 | $429.75M | $-22.64M | $-26.44 |
| 2018 | $229.21M | $-116.44M | $-156.00 |
| 2017 | $181.10M | $-67.86M | $-100.00 |
| 2016 | $130.08M | $-86.35M | $-164.00 |
| 2015 | $81.76M | $-115.20M | $-332.00 |
| 2014 | $54.20M | $-56.36M | $-128.00 |
| 2013 | $26.35M | $-166.23M | $-412.00 |
| 2012 | $0.00 | $-179.18M | $-496.00 |
Valuation
AMRNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·13d ago·Neutral
…proteins at American Heart Association (AHA) Scientific Sessions 2026 DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data evaluating lipoprotein(a) [Lp(a)] and other apolipoprotein B (apoB) containing lipoproteins as predictors of major adverse cardiovascular events (MACE), as well as new mechanistic findings examining the effect…
View source ↗ - Newszacks.com·24d ago·Neutral
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
What Amarin (AMRN) Said on Its Q3 Earnings Call Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset continued U.S. pricing pressure for its VASCEPA cardiovascular therapy.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…ts 2026 Third Quarter Financial Results, Achieves Positive Net Income DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share lead…
View source ↗ - Newsglobenewswire.com·28d ago·Negative
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VA
View source ↗ - Newszacks.com·74d ago·Negative
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
View source ↗ - Newsglobenewswire.com·83d ago·Neutral
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
View source ↗ - Newsglobenewswire.com·86d ago·Negative
…fit Following Icosapent Ethyl Treatment Cessation in Adherent Patients DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
View source ↗ - Newsglobenewswire.com·90d ago·Negative
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.08 per share
Typical surprise -85.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$0.08 vs $-0.10beat
- Wed, Jul 29$-0.02 vs $-0.01miss
- Wed, Apr 29$-0.09 vs $0.01miss
- Wed, Feb 25$0.01 vs $0.07miss
- Wed, Oct 29$0.01 vs $0.08miss
- Wed, Jul 30$-0.03 vs $-0.66beat
Estimates and results for AMRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMRN officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AMRN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
